Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Uric Acid Metabolism in the Pathophysiology of Ischaemic Heart Disease
Author(s): Federica Piani , Lorenzo Annesi , Claudio Borghi Added: 5 months ago

Heart Failure

Prevention & Chronic Conditions
AHA 24: New Insights from CLEAR OUTCOMES
Author(s): Marc P Bonaca Added: 11 months ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,… View more

Vascular Disease and Surgery

Prevention & Chronic Conditions
EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 1 month ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more

Heart Failure

Prevention & Chronic Conditions
Job title: Director
AHA 24: The ALPACAR Trial
Author(s): Steven E Nissen Added: 11 months ago
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial… View more

Prevention & Chronic Conditions
AHA 23: Preventive Cardiology in 2023
Author(s): Michael Honigberg Added: 1 year ago
AHA 23 — Dr Michael Honigberg (Massachusetts General Hospital, US) highlights key 2023 cardiology updates, featuring novel data from AHA Scientific Sessions.Dr Honigberg provides commentary on the new SELECT trial outcomes and emphasises the incretin mimetic, semaglutide's role in cardiovascular medicine. He delves into lipid management with a focus on the CLEAR trial data and the incorporation… View more

Guidelines & Statements

Prevention & Chronic Conditions
Treatment Options and Continuity of Care in MAFLD
Author(s): Carmen Lara-Romero , Manuel Romero-Gómez Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Andrew Mente
Job title: Associate Professor – Department of Health Research Methods, Evidence, and Impact (HEI)
Dr Andrew Mente is a Principal Investigator for the Epidemiology program at the Population Health Research Institute and Associate Professor – Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University. Dr Mente received his doctoral degree in Epidemiology from the University of Toronto and completed post-doctoral training in cardiovascular epidemiology at McMaster… View more
Job title: PhD, RD, FHFSA, FASPEN
Dr Salvatore Carbone, PhD, RDN, MS, FHFSA, FASPEN is an Associate Professor and Program Director of the Nutrition Program at the EVMS School of Health Professions, and an Associate Professor within the EVMS Division of Endocrine and Metabolic Disorders, Strelitz Diabetes Center, Department of Internal Medicine, at the Macon & Joan Brock Virginia Health Sciences at Old Dominion University… View more
Cardiovascular Effects of NSAIDs: A Review With a Focus on RA Patients
Author(s): Eirik Ikdahl , Anne Kerola , Eli Sollerud , et al Added: 10 months ago

Prevention & Chronic Conditions